Actively Recruiting
Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Led by Centre Leon Berard · Updated on 2026-03-31
236
Participants Needed
12
Research Sites
678 weeks
Total Duration
On this page
Sponsors
C
Centre Leon Berard
Lead Sponsor
N
National Cancer Institute, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Testicular germ cell tumor (TGCT) is the most common malignancy in men between 15 and 40 years. Although TCGT survivors have a good survival prognosis, they suffer from short- and long-term sequelae such as chronic fatigue, psychological disorders, cardiovascular toxicities and second malignancies. The benefits of physical activity (PA) during treatments have been demonstrated in cancer patients to improve quality of life (QoL) and physical fitness and to reduce fatigue. However, few PA programs have been proposed to TGCT patients and their effects on sequelae have not been assessed yet. A growing body of evidence links treatment-related alteration in the gut microbiota to sequelae of cancer survivors, including fatigue and cardiovascular toxicities. Also, PA has been known as a possible modulator of the gut microbiota composition. To date, no study has been conducted to examine how the gut microbiota and its metabolites moderate the effect of PA on fatigue and other late effects in TGCT survivors. The objectives will be to assess the impact of a PA program on fatigue and other sequelae and to investigate how the gut microbiota and its metabolites moderate the associations between PA and sequelae. We will conduct a prospective, multicenter, phase III, randomized controlled trial of a one-year supervised PA program. 236 men with metastatic TGCT and eligible for a first line of chemotherapy will be randomly assigned to either PA intervention or control arm. All patients will benefit from a connected activity tracker and PA recommendations. In the intervention arm, PA will be based on supervised sessions and motivational interviews. The primary endpoint (fatigue) will be assessed at 3 years. The trial will provide novel insights into the impact of PA on fatigue and other sequelae in TGCT survivors with understanding a potential underlying mechanism of gut microbiota. This evidence will support the development of targeted PA guidelines to improve QoL and reduce sequelae in TGCT survivors.
CONDITIONS
Official Title
Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men 18 years or older
- Diagnosed with metastatic germ cell tumor confirmed by tissue examination (seminoma or non-seminoma)
- Planned first-line chemotherapy with BEP, EP, or VIP
- Own a smartphone to connect with an activity tracker
- Performance status of 2 or less
- Medical certificate confirming ability to practice adapted physical activity
- Willing and available to participate for the study duration
- Able to understand, read, and write French
- Covered by a social security plan
- Signed informed consent form
You will not qualify if you...
- Having symptomatic bone or brain metastases
- Central nervous system issues causing walking difficulties
- History or coexistence of another primary cancer except certain in situ cancers, basal cell skin cancer, or cancers in complete remission over 3 years
- Contraindications to physical activity such as uncontrolled hypertension or heart disease
- Unable to be followed medically or socially for the study duration
- Legally deprived of liberty or protected adults
- Participating in another physical activity study concurrently
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Institut de Cancérologie de Lorraine
Angers, France, 49000
Not Yet Recruiting
2
CHU Jean Minjoz
Besançon, France, 25030
Not Yet Recruiting
3
Institut Bergonié
Bordeaux, France, 33000
Not Yet Recruiting
4
Centre François Baclesse
Caen, France, 14076
Not Yet Recruiting
5
Centre Oscar Lambret
Lille, France, 59020
Not Yet Recruiting
6
Centre Leon Berard
Lyon, France, 69008
Actively Recruiting
7
Institut de Cancérologie de Lorraine
Nancy, France, 54519
Actively Recruiting
8
Centre Antoine Lacassagne
Nice, France, 06189
Not Yet Recruiting
9
AP-HP Tenon
Paris, France, 75020
Not Yet Recruiting
10
Centre Eugène Marquis
Rennes, France, 35000
Not Yet Recruiting
11
CHU Tours
Tours, France, 37000
Not Yet Recruiting
12
Institut Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
Research Team
C
Carmen Dupuis, PhD
CONTACT
O
Olivia Pérol, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here